68. Allen TM (2002) Ligand-targeted therapeutics in anticancer therapy. Nat Rev Cancer 2:
750–763
69. Ruoslahti E, Bhatia SN, Sailor MJ (2010) Targeting of drugs and nanoparticles to tumors.
J Cell Biol 188:759–768
70. Wiley DT, Webster P, Gale A, Davis M (2013) Transcytosis and brain uptake of transferrincontaining nanoparticles by tuning avidity to transferrin receptor. Proc Natl Acad Sci U S A
110:8662–8667
71. Rajendran L, Kno ¨lker H-J, Simons K (2010) Subcellular targeting strategies for drug design
and delivery. Nat Rev Drug Discov 9:29–42
72. Murakami M, Cabral H, Matsumoto Y, Wu S, Kano MR, Yamori T, Nishiyama N, Kataoka K
(2011) Improving drug potency and efficacy by nanocarrier-mediated subcellular targeting.
Sci Transl Med 3:64ra2
73. Miyata K, Nishiyama N, Kataoka K (2012) Rational design of smart supramolecular assemblies
for gene delivery: chemical challenges in the creation of artificial viruses. Chem Soc Rev
41:2562–2574
74. Torchilin VP (2008) Cell penetrating peptide-modified pharmaceutical nanocarriers for intracellular drug and gene delivery. Biopolymers 90:604–610
75. Rangel R, Guzman-Rojas L, le Roux LG, Staquicini FI, Hosoya H, Barbu EM, Ozawa MG,
Nie J, Dunner K Jr, Langley RR, Sage EH, Koivunen E, Gelovani JR, Lobb RR, Sidman RL,
Pasqualini R, Arap W (2012) Combinatorial targeting and discovery of ligand-receptors in
organelles of mammalian cells. Nat Commun 3:788
76. Cabral H, Nishiyama N, Kataoka K (2011) Supramolecular nanodevices: from design validation
to theranostic nanomedicine. Acc Chem Res 44:999–1008
262
H. Cabral and K. Kataoka